



16

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
July 19, 2004 Date	 Gina N. Shishima

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Ratain et al.

Serial No.: 10/057,834

Filed: January 25, 2002

For: Compositions and Methods for Optimizing  
UGT2B7 Substrate Dosings and for  
Predicting UGT2B7 Substrate Toxicity

Group Art Unit: 1634

Examiner: Myers, Carla J.

Atty. Dkt. No.: ARCD:358US

**RESPONSE TO RESTRICTION REQUIREMENT DATED JUNE 17, 2004**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Commissioner:

This paper is submitted in response to the Restriction Requirement dated June 17, 2004 for which the date for response is July 17, 2004, which is a Saturday. Therefore, this response is timely filed.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/ARCD:358US.

In response to the restriction requirement which the Examiner imposed, Applicants elect, without traverse, to prosecute claims 1-100, *i.e.*, the Group I claims.

Applicants also elect epirubicin as the drug species. The following claims are believed to be readable on this species: 1-18, 41, 43, 66, 68-71, and 94-100. Should subject matter of any claim generic with respect to the drug species be held allowable, Applicants reserve the right to have the claims reciting other species examined and allowed.

The Examiner is invited to contact the undersigned attorney at (512) 536-3081 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Gina N. Shishima  
Reg. No. 45,104  
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201  
(512) 536-4598 (facsimile)

Date: July 19, 2004



JFW  
634

# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

GSHISHIMA@FULBRIGHT.COM  
DIRECT DIAL: (512) 536-3081

TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

July 19, 2004

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
July 19, 2004 Date	 Gina N. Shishima

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Re: SN 10/057,834 entitled "Compositions and Methods for Optimizing UGT2B7 Substrate Dosings and for Predicting UGT2B7 Substrate Toxicity" by Ratain et al.  
Our ref: ARCD:358US      Client ref: UCHI:846

Commissioner:

Enclosed for filing in the above-referenced patent application are the following:

- (1) Response to Restriction Requirement Dated June 17, 2004; and
- (2) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

It is believed that no fee is due. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/ARCD:358US.

Very truly yours,

Gina N. Shishima  
Reg. No. 45,104

GNS/ld  
Enclosures

25434736.1